Journal profile · Biochemistry, Genetics and Molecular Biology-Biotechnology
Nanobiomedicine
ISSN 1849-5435 · SAGE · United Kingdom
Nanobiomedicine: fully open access; APC about USD 2,000; review about 14 weeks (community reports); 0 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Nanobiomedicine is published by SAGE. By OpenAlex counts of its recent articles, its largest topics are Nanoparticle-Based Drug Delivery, Nanoparticles: synthesis and applications and Gold and Silver Nanoparticles Synthesis and Applications, together about 37.7% of its articles. Its main subfields are Biomedical Engineering. (generated from OpenAlex topic counts and CAS ranking data)
Nanobiomedicine (NAB) is a peer-reviewed, open access journal which focusses on research in nanotechnology as it interfaces with fundamental studie...
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Biotechnology
Editor-in-chief Winston KuoPublisher website
Editorial board by country: 3 in mainland China (about 6%); most named United States 26, Italy 5, Mainland China 3, Canada 3, Japan 2 (54 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoparticle-Based Drug DeliveryMaterials Science17.4%
- Nanoparticles: synthesis and applicationsMaterials Science10.2%
- Gold and Silver Nanoparticles Synthesis and ApplicationsMaterials Science10.2%
- Nanoplatforms for cancer theranosticsEngineering7.1%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics6.1%
- Biosensors and Analytical DetectionEngineering5.1%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology4.1%
- Advanced biosensing and bioanalysis techniquesBiochemistry, Genetics and Molecular Biology3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Biomedical Engineering | Q2 | 95/303 | — |
| Biotechnology | Q2 | 101/311 | — |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 6.8LetPub ·
- SJR 2026-06
- 0.48LetPub ·
- SNIP 2026-06
- 0.24LetPub ·
- h-index
- 25OpenAlex ·
- i10-index
- 30OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 52 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 0 | 0 | 145 |
| 2025 | 0 | 0 | 226 |
| 2024 | 0 | 0 | 275 |
| 2023 | 0 | 0 | 274 |
| 2022 | 1 | 1 | 299 |
| 2021 | 2 | 2 | 271 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 14 weeksLetPub ·
- Peer review
- Double blind peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,000 | — | — | |
| LetPub | USD 2,000 | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- SAGE
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1849-5435
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Nanobiomedicine
How long does peer review take at Nanobiomedicine?
Authors report an average review time of about 14 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Nanobiomedicine based?
Of the 54 board members whose country the journal's board page names, 3 (about 6%) are in mainland China; the countries named most often are United States (26), Italy (5) and Mainland China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Nanobiomedicine?
According to LetPub and DOAJ records, Nanobiomedicine is indexed in Scopus.
Is Nanobiomedicine open access, and what is the APC?
Nanobiomedicine is a fully open-access journal. APC about USD 2,000.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .